These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38211572)

  • 21. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
    Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tsuji K; Kurosaki M; Itakura J; Mori N; Takaki S; Hasebe C; Akahane T; Joko K; Yagisawa H; Takezawa J; Nakata R; Kusakabe A; Kojima Y; Kimura H; Tamada T; Kobashi H; Mitsuda A; Kondou M; Ogawa C; Uchida Y; Sohda T; Narita R; Izumi N
    J Gastroenterol; 2018 Oct; 53(10):1142-1150. PubMed ID: 29626296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.
    Kikukawa K; Uchida-Kobayashi S; Tamori A; Yoshida K; Kotani K; Motoyama H; Kozuka R; Hagihara A; Fujii H; Morikawa H; Enomoto M; Murakami Y; Kawada N
    Ann Hepatol; 2020; 19(4):367-372. PubMed ID: 32444247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
    Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
    Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
    Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
    J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
    Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
    Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
    Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
    Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    Ohama H; Hiraoka A; Tada T; Kariyama K; Itobayashi E; Tsuji K; Ishikawa T; Toyoda H; Hatanaka T; Kakizaki S; Naganuma A; Tada F; Tanaka H; Nakamura S; Nouso K; Tanaka K; Kumada T;
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1394-1402. PubMed ID: 38602340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
    Hayes CN; Zhang P; Zhang Y; Chayama K
    Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
    Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
    Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
    J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
    Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
    J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.